Umeclidinium bromide

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Umeclidinium bromide
Umeclidinium bromide.svg
Umeclidinium bromide 3D.png
Clinical data
Trade namesIncruse Ellipta
Other namesGSK573719A
License data
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
Inhalation (DPI)
ATC code
Legal status
Legal status
  • US: ℞-only
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding~89%[1]
MetabolismHepatic (CYP2D6)
Elimination half-life11 hours
ExcretionFeces (58%) and urine (22%)
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
CompTox Dashboard (EPA)
ECHA InfoCard100.166.375 Edit this at Wikidata
Chemical and physical data
FormulaC29H34BrNO2
Molar mass508.500 g·mol−1
3D model (JSmol)

Umeclidinium bromide (trade name Incruse Ellipta) is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD).[1] It is also approved for this indication in combination with vilanterol (as umeclidinium bromide/vilanterol)[2][3] and also as a triple-therapy combination as fluticasone furoate/umeclidinium bromide/vilanterol.[4]

External links[edit]

References[edit]

  1. ^ a b "Incruse Ellipta (umeclidinium inhalation powder) for Oral Inhalation Use. Full Prescribing Information" (PDF). GlaxoSmithKline, Research Triangle Park, NC 27709. Retrieved 22 February 2016.
  2. ^ Feldman GJ, Edin A (December 2013). "The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects". Therapeutic Advances in Respiratory Disease. 7 (6): 311–9. doi:10.1177/1753465813499789. PMID 24004659.
  3. ^ "FDA Approves Umeclidinium and Vilanterol Combo for COPD". Medscape. December 18, 2013.
  4. ^ "TRELEGY ELLIPTA Package Insert" (PDF). GlaxoSmithKline. September 2017. Retrieved 11 July 2020.